Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
18.57
-2.84 (-13.26%)
At close: Nov 15, 2024, 4:00 PM
18.85
+0.28 (1.51%)
After-hours: Nov 15, 2024, 5:00 PM EST
Arrowhead Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for ARWR stock have an average target of 45.33, with a low estimate of 27 and a high estimate of 62. The average target predicts an increase of 144.10% from the current stock price of 18.57.
Analyst Consensus: Buy
* Price targets were last updated on Oct 11, 2024.
Analyst Ratings
The average analyst rating for ARWR stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 4 | 4 | 4 | 4 |
| Buy | 3 | 2 | 2 | 3 | 4 | 4 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 8 | 9 | 10 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +223.10% | Oct 11, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $62 | Buy | Reiterates | $62 | +233.87% | Oct 8, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $42 | Buy | Reiterates | $42 | +126.17% | Sep 26, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +223.10% | Sep 5, 2024 |
Financial Forecast
Revenue This Year
76.43M
from 240.74M
Decreased by -68.25%
Revenue Next Year
153.59M
from 76.43M
Increased by 100.95%
EPS This Year
-4.83
from -1.92
EPS Next Year
-4.31
from -4.83
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 266.3M | 464.8M | 423.2M | |||
| Avg | 76.4M | 153.6M | 245.0M | |||
| Low | 3.5M | n/a | 111.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 10.6% | 508.2% | 175.5% | |||
| Avg | -68.3% | 101.0% | 59.5% | |||
| Low | -98.6% | - | -27.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.78 | -1.85 | -1.49 | |||
| Avg | -4.83 | -4.31 | -3.79 | |||
| Low | -5.16 | -6.16 | -5.78 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.